Patents by Inventor Joung L. Goulet

Joung L. Goulet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimisazo[4,5-f]isoquinolinone derivatives
    Patent number: 6852727
    Abstract: Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: February 8, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Joung L. Goulet, Rose M. Cubbon, Richard T. Cummings, Xingfang Hong, Peter J. Sinclair, James E. Thompson
  • (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
    Patent number: 6809199
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 26, 2004
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • Benzimisazo[4,5-f]isoquinolinone derivatives
    Publication number: 20040176601
    Abstract: Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.
    Type: Application
    Filed: January 30, 2004
    Publication date: September 9, 2004
    Inventors: Joung L. Goulet, Rose M Cubbon, Richard T Cummings, Xingfang Hong, Peter J Sinclair, James E Thompson
  • (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
    Publication number: 20030092712
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: December 17, 2001
    Publication date: May 15, 2003
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • Src kinase inhibitor compounds
    Patent number: 6498165
    Abstract: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: December 24, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Helen M. Armstrong, Richard Beresis, Joung L. Goulet, Mark A. Holmes, Xingfang Hong, Sander G. Mills, William H. Parsons, Peter J. Sinclair, Mark G. Steiner, Frederick Wong, Dennis M. Zaller
  • SRC kinase inhibitor compounds
    Patent number: 6329380
    Abstract: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of proteins tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: December 11, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Joung L. Goulet, Mark A. Holmes, Julianne A. Hunt, Sander G. Mills, William H. Parsons, Peter J. Sinclair, Dennis M. Zaller
  • Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
    Patent number: 5679700
    Abstract: Novel phosphinic acid-containing peptidyl compounds of formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophobic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. These inhibitors may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to permanent disability. These compounds may also have utility as a means for birth control by preventing ovulation or implantation.
    Type: Grant
    Filed: November 9, 1995
    Date of Patent: October 21, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Charles G. Caldwell, Philippe L. Durette, Joung L. Goulet, William K. Hagmann, Soumya P. Sahoo